Table 2 Characteristics of patients with inadequate response to treatment or relapse
Pt | Age | HAQ at t0 | Months of treatment/withdrawal | DMARD/mean GC oral dose (mg/d) | Previous treatment | PCR/CCR (months to event) | Persisting clinical symptoms | PLR/CLR (months to event) | Persisting biological activity | Relapse (months to event) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 24 | 3 | 3/drug toxicity | CyA/16 | GC | PCR (1) | Arthralgias | PLR (1) | ↑ WBC, ↑ Ferritin, ↑ Liver enzymes | No |
2 | 16 | 1.25 | 6/disease flare | MTX/8 | MTX+GC +ETN | PCR (1) | Fever, Arthritis | PLR (1) | Anemia, ↑ WBC, ↑ PLTs, ↑ CRP, ↑ ESR, ↑ Ferritin | Yes (4) |
3 | 56 | 2.5 | 3/drug toxicity | None/0 | GC | PCR (0.01) | Arthralgias | PLR (1) | Anemia, ↑ Ferritin | No |
4 | 64 | 1.5 | 1.5/drug toxicity | LEF/3 | MTX+GC | CCR (1) | - | PLR (1) | Anemia, ↑ ESR | No |
5 | 48 | 2.5 | 14/follow up end | MTX for the last 8 months/18.25 | GC | PCR (0.5)/CCR (8) | Arthralgias/Arthritis | PLR (1)/CLR (9) | ↑ WBC, ↑ CRP | Yes (5) |
6 | 32 | 1.8 | 4/no response | MTX/4 | MTX+GC +ETN, then ADA | No response | Arthralgias/Arthritis | No response | Anemia, ↑ WBC, ↑ PLTs, ↑ CRP, ↑ ESR, ↑ Ferritin | - |
7 | 49 | 3 | 15/follow up end | MTX for the last 2 months/18.6 | GC | CCR (0.2 and 13.5) | - | CLR (1 and 14) | - | Yes (13 e.g. 4 months after reducing anakinra dosing) |